يعرض 1 - 6 نتائج من 6 نتيجة بحث عن '"Laird, AD"', وقت الاستعلام: 0.38s تنقيح النتائج
  1. 1
    Academic Journal

    المساهمون: Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Manchester, UK.

    Relation: https://dx.doi.org/10.1038/s41523-023-00561-y; Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ breast cancer. 2023 OCT 6;9(1). PubMed PMID: WOS:001093163100001. English.; http://hdl.handle.net/10541/626718; NPJ Breast Cancer

  2. 2
    Academic Journal

    Relation: NHMRC/1140626; pii: S0006-4971(22)00245-2; Kimura, S., Montefiori, L., Iacobucci, I., Zhao, Y., Gao, Q., Paietta, E. M., Haferlach, C., Laird, A. D., Mead, P. E., Gu, Z., Stock, W., Litzow, M., Rowe, J. M., Luger, S. M., Hunger, S. P., Ryland, G. L., Schmidt, B., Ekert, P. G., Oshlack, A. ,. Mullighan, C. G. (2022). Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. BLOOD, 139 (24), pp.3519-3531. https://doi.org/10.1182/blood.2022015444.; http://hdl.handle.net/11343/333605

  3. 3
  4. 4
    Conference

    المساهمون: Molecular Oncology, Royal Marsden Hospital, The Institute of Cancer Research, London

    Relation: https://dx.doi.org/10.1093/annonc/mdz242.009; Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. 314P Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations. Annals of Oncology. 2019;30(Supplement_5):108.; http://hdl.handle.net/10541/622581; Annals of Oncology

  5. 5
  6. 6